Trials / Withdrawn
WithdrawnNCT02730364
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Pheniramine Maleate 20 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respiratory Tract Infection
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the short term efficacy of the Theraflu Night powder for oral solution in the Russian population in "Short term relief of the symptoms of colds, chills and influenza, including mild to moderate pain, fever and nasal congestion".
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C | One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution. |
Timeline
- Start date
- 2017-02-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2016-04-06
- Last updated
- 2018-03-12
Source: ClinicalTrials.gov record NCT02730364. Inclusion in this directory is not an endorsement.